These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 20869898)

  • 1. Interleukin-6: from identification of the cytokine to development of targeted treatments.
    Assier E; Boissier MC; Dayer JM
    Joint Bone Spine; 2010 Dec; 77(6):532-6. PubMed ID: 20869898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-6--a key mediator of systemic and local symptoms in rheumatoid arthritis.
    Cronstein BN
    Bull NYU Hosp Jt Dis; 2007; 65 Suppl 1():S11-5. PubMed ID: 17708739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Humanized antihuman IL-6 receptor antibody, tocilizumab.
    Nishimoto N; Kishimoto T
    Handb Exp Pharmacol; 2008; (181):151-60. PubMed ID: 18071945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibiting interleukin-6 in rheumatoid arthritis.
    Choy E
    Curr Rheumatol Rep; 2008 Oct; 10(5):413-7. PubMed ID: 18817647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Profile of sarilumab and its potential in the treatment of rheumatoid arthritis.
    Raimondo MG; Biggioggero M; Crotti C; Becciolini A; Favalli EG
    Drug Des Devel Ther; 2017; 11():1593-1603. PubMed ID: 28579757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in immunopathophysiology of interleukin-6: an innovative therapeutic drug, tocilizumab (recombinant humanized anti-human interleukin-6 receptor antibody), unveils the mysterious etiology of immune-mediated inflammatory diseases.
    Ohsugi Y
    Biol Pharm Bull; 2007 Nov; 30(11):2001-6. PubMed ID: 17978466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-interleukin-6 therapy in rheumatoid arthritis.
    Woodrick R; Ruderman EM
    Bull NYU Hosp Jt Dis; 2010; 68(3):211-7. PubMed ID: 20969554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An affibody-adalimumab hybrid blocks combined IL-6 and TNF-triggered serum amyloid A secretion in vivo.
    Yu F; Gudmundsdotter L; Akal A; Gunneriusson E; Frejd F; Nygren PÅ
    MAbs; 2014; 6(6):1598-607. PubMed ID: 25484067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of interleukin-6 classic- and trans-signaling on liver damage and regeneration.
    Drucker C; Gewiese J; Malchow S; Scheller J; Rose-John S
    J Autoimmun; 2010 Feb; 34(1):29-37. PubMed ID: 19717281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-6 in rheumatoid arthritis.
    Nishimoto N
    Curr Opin Rheumatol; 2006 May; 18(3):277-81. PubMed ID: 16582692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IL-6 inhibitors for treatment of rheumatoid arthritis: past, present, and future.
    Kim GW; Lee NR; Pi RH; Lim YS; Lee YM; Lee JM; Jeong HS; Chung SH
    Arch Pharm Res; 2015; 38(5):575-84. PubMed ID: 25648633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting Interleukin-6 Signaling in Clinic.
    Kang S; Tanaka T; Narazaki M; Kishimoto T
    Immunity; 2019 Apr; 50(4):1007-1023. PubMed ID: 30995492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [New approaches to pharmacotherapy for rheumatoid arthritis: perspective for use of tocilizumab (monoclonal antibodies to interleukin-6 receptor)].
    Nasonov EL
    Ter Arkh; 2010; 82(5):64-71. PubMed ID: 20597275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-IL-6 receptor antibody (tocilizumab): a B cell targeting therapy.
    Snir A; Kessel A; Haj T; Rosner I; Slobodin G; Toubi E
    Clin Exp Rheumatol; 2011; 29(4):697-700. PubMed ID: 21813064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-6 inhibition and clinical efficacy in rheumatoid arthritis treatment--data from randomized clinical trials.
    Kavanaugh A
    Bull NYU Hosp Jt Dis; 2007; 65 Suppl 1():S16-20. PubMed ID: 17708740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-interleukin-6 receptor antibody therapy in rheumatic diseases.
    Nakahara H; Nishimoto N
    Endocr Metab Immune Disord Drug Targets; 2006 Dec; 6(4):373-81. PubMed ID: 17214583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL-6 controls the innate immune response against Listeria monocytogenes via classical IL-6 signaling.
    Hoge J; Yan I; Jänner N; Schumacher V; Chalaris A; Steinmetz OM; Engel DR; Scheller J; Rose-John S; Mittrücker HW
    J Immunol; 2013 Jan; 190(2):703-11. PubMed ID: 23241882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-6 and rheumatic diseases.
    Lipsky PE
    Arthritis Res Ther; 2006; 8 Suppl 2(Suppl 2):S4. PubMed ID: 16899108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-6 as a key player in systemic inflammation and joint destruction.
    Fonseca JE; Santos MJ; Canhão H; Choy E
    Autoimmun Rev; 2009 Jun; 8(7):538-42. PubMed ID: 19189867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What's the Difference?
    Avci AB; Feist E; Burmester GR
    BioDrugs; 2018 Dec; 32(6):531-546. PubMed ID: 30488231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.